IgA Nephropathy
Advertisement
Researchers studied the effect of intensive blood pressure control on the progression of IgAN.
FILSPARI (sparsentan) has received conditional marketing authorization from the European Commission to treat IgAN in adults.
Interim analysis from the APPLAUSE-IgAN trial found favorable results for the use of iptacopan in IgAN.
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
Vertex Pharmaceuticals will acquire Alpine Immune Sciences, developer of povetacicept for IgA nephropathy.
Results from a trial of atacicept for the treatment of IgAN will be presented at the European Renal Association Congress.
Results of the RUBY-3 study of povetacicept for IgAN will be presented at the ISN World Congress of Nephrology.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
Dr. Richard Lafayette discusses the FDA approval of TARPEYO as treatment for adults with IgA nephropathy.
Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis.
Clinical manifestations associated with IgAN include hematuria, proteinuria, and hypertension.
Where patients reported nausea/vomiting, it was not recognized by nephrologists in 85% of cases.
Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis.
The FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria ...
A study sought to discern surrogate endpoints that could serve as robust predictors of treatment efficacy on long-term ...
A study shows that sustained proteinuria is a strong predictor for the rate of progression of renal disease, and ...
Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease and a major cause of kidney ...
In a recent clinical trial, researchers led by Gaiqin Pei, MM, sought to examine the effect of immunosuppression ...
Immunoglobulin A nephrology (IgAN) is the most common biopsy-proven glomerular disease. Patients who develop IgAN ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.